• 1.

    Jennette JC, et al.. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:111.

  • 2.

    Lionaki S, et al.. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64:34523462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Cornec D, et al.. ANCA-associated vasculitis—clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 2016; 12:570579.

  • 4.

    Merkel PA, et al.. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol 2017; 69:10541066.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Pendergraft WF, 3rd, Niles JL. Trojan horses: Drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014; 26:4249.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Scott DG, Watts RA. Epidemiology and clinical features of systemic vasculitis. Clin Exp Nephrol 2013; 17:607610.

  • 7.

    Jennette JC, Falk RJ. Small vessel vasculitis. N Engl J Med 1997; 337:15121523.

  • 8.

    Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014; 10:463473.

  • 9.

    Jayne D, Rasmussen N. Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. Nephrol Dial Transplant 2015; 30[Suppl] 1:i1–i7.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    McGregor JG, et al.. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 2015; 30[Suppl 1]:i171i181.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Jones RB, et al.. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211220.

  • 12.

    Stone JH, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221232.

  • 13.

    Guillevin L, et al.. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371:17711780.

  • 14.

    Miloslavsky EM, et al.. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013; 65:24412449.

    • Crossref
    • Search Google Scholar
    • Export Citation

ANCA Disease: What’s in a Name?

  • 1 J. Charles Jennette, MD, is the Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine and executive director of the University of North Carolina nephropathology division at the University of North Carolina at Chapel Hill.
  • | 2 Ronald J. Falk, MD, is the Nan and Hugh Cullman Eminent Professor and Chair of Medicine and director of the University of North Carolina Kidney Center at the University of North Carolina at Chapel Hill.
Restricted access
Save